RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth +5.6% ·
share flow -14.4% ·
net new positions 0.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 144 | 0 | 302.77M | $16.97B | +5 | −6 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | n/a |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | n/a | n/a |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | n/a | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | n/a |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | n/a | 58.59M | $1.54B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 44.16M | n/a | $1.56B | 0.1% | n/c | 1 | SEC ↗ ×14 |
| 2 | Fidelity (FMR) ✦ | 27.99M | -30.6% | $987.37M | 0.1% | ▼ Trim | 2 | SEC ↗ ×7 |
| 3 | BlackRock ✦ (passive) | 26.20M | +3.0% | $924.35M | 0.0% | ▲ Add | 2 | SEC ↗ ×20 |
| 4 | Baillie Gifford ✦ | 17.37M | -3.6% | $612.90M | 0.5% | ▼ Trim | 6 | SEC ↗ ×4 |
| 5 | Adage Capital Partners ✦ | 11.97M | +99.4% | $422.15M | 0.7% | ▲ Add | 6 | SEC ↗ |
| 6 | The Vanguard Group ✦ (passive) | 10.94M | -69.9% | $385.84M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 7 | State Street Global Advisors ✦ (passive) | 10.27M | +0.8% | $362.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 7.62M | -6.8% | $268.03M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | JPMorgan Chase ✦ | 3.52M | n/a | $124.16M | 0.0% | n/c | 1 | SEC ↗ ×24 |
| 10 | Arrowstreet Capital ✦ | 3.28M | +10.3% | $115.80M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 11 | Millennium Management ✦ | 2.24M | +379.2% | $78.86M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 1.96M | +12.9% | $69.19M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 13 | Goldman Sachs Group ✦ | 1.65M | n/a | $58.06M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Marshall Wace ✦ | 1.48M | New | $52.34M | 0.1% | New | 1 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 1.18M | +2089.0% | $41.78M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 1.03M | +271.9% | $36.37M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | Citadel Advisors ✦ | 394.67K | -25.1% | $13.92M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 140.03K | +314.3% | $4.94M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | Wellington Management ✦ | 6.87K | New | $242,479 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $52.34M | 0.1% |
| Wellington Management | $242,479 | 0.0% |
Exited
| Norges Bank | $181.39M | was 0.0% |
| Viking Global Investors | $93.59M | was 0.3% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 583 holders, 354.58M shares, $16.55B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.13K sh · $238,813
Officer · 96.07K sh · $5.62M
Officer · 3.93K sh · $231,403
Officer · 100.00K sh · $6.00M
Officer · 9.23K sh · $540,752
Officer · 1.77K sh · $104,799
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
18.7% of class · View original SEC filing ↗
4.8% of class · View original SEC filing ↗